Displaying 2061 - 2080 of 2348
Boston Scientific Corporation, U.S.
FTC Charges Unocal with Anticompetitive Conduct Related to Reformulated Gasoline
First Session of FTC/DOJ Health Care and Competition Law and Policy Hearings Begins Wednesday, February 26
Resolving Anticompetitive Concerns, FTC Clears Dainippon's Acquisition of Bayer Corp.'s High-Performance Organic Pigment Business
Improving the Economic Foundations of Competition Policy
FTC Competition Director Announces Best Practices for Merger Investigations
Looking Forward: The Federal Trade Commission and the Future Development of U.S. Competition Policy
FTC Releases Health Care and Competition Law and Policy Workshop Materials
Efficiencies and Antitrust: A Story of Ongoing Evolution
Possible Anticompetitive Efforts to Restrict Competition on the Internet
Workshop on Health Care and Competition Law and Policy
Federal Trade Commission Announces Formation of Merger Litigation Task Force
Physician Integrated Services of Denver, Inc., Michael J. Guese, M.D., and Marcia L. Brauchler
Aurora Associated Primary Care Physicians, L.L.C., Richard A. Patt, M.D., Gary L. Gaede, M.D., and Marcia L. Brauchler
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.
FTC Merger Best Practices
Addressing Competitive Concerns in Core Markets, FTC Approves Bayer AG'S Acquisition of Aventis CropScience Holdings S.A.
Displaying 2061 - 2080 of 2348